CTIS2023-505898-32-00招募中1 期
A Phase 1/2, Open-Label, Randomized, Dose Finding and Dose Expansion Study of Gedatolisib in Combination with Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - CELC-G-201
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- Male
入选标准
- •1.Adult males =18 years of age, 10.Completion of prior treatment with an androgen receptor inhibitor (ARi) =4 weeks before first dose of study drug or =2 weeks if the therminal ARi half-life is <24 hours, 11.At least 2 weeks beyond treatment with a targeted therapy or major surgery and at least 3 weeks beyond any other systemic anticancer therapy and/or radiation therapy, and resolution of all toxicities related to prior therapies or surgical procedures to baseline (except alopecia, Grade 1 peripheral neuropathy), 12.Adequate bone marrow, hepatic, renal and coagulation function, 13.Must be willing and able to comply with protocol-specified schedules of assessments, treatment plans, laboratory tests, and other study procedures, 14.Must agree to follow the contraception requirements for the duration of the active treatment period and for at least 12 weeks after the last dose of study treatment, 15.Ability to understand the investigational nature of the study and sign the informed consent form, 2.Histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate without a small cell component and with <10% neuroendocrine type cells, 3.Subjects must have metastatic castration-resistant prostate cancer (mCRPC; i.e., developed progression of metastases following surgical castration or during medical androgen ablation therapy), 4.Metastatic disease identified by conventional imaging: computed tomography (CT), magnetic resonance imaging (MRI), or technetium 99m methyl diphosphonate (99mTc MDP) bone scintigraphy. Measurable and non measurable disease are allowed, but metastases visible only on prostate-specific membrane antigen (PSMA) positron emission tomography (PET) will not be allowed for eligibility purposes., 5.Progressive mCRPC based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 with modifications as specified in Prostate Cancer Working Group 3 (PCWG3) criteria as defined by at least one of the following criteria: a.Prostate-specific antigen (PSA) progression defined as a minimum of 2 rising PSA levels with a minimum of a 1 week interval between each determination. A minimum PSA of 1.0 ng/mL is required for study entry. b.Soft-tissue progression defined as an increase =20% in the sum of the longest diameter (LD) of all target lesions based on the smallest sum LD since treatment started or the appearance of one or more new lesions. c.Progression of bone disease (measurable disease) or 2 or more new bone lesions by bone scan., 6.Continued primary androgen deprivation with luteinizing hormone-releasing hormone (LHRH) analog (agonist or antagonist) if subject has not undergone bilateral orchiectomy, 7.Eastern Cooperative Oncology Group (ECOG) performance status score =1, 8.Life expectancy of at least 3 months, 9.Subjects must meet the following prior therapy criteria: a. Progression on or after treatment with one next generation androgen receptor signaling inhibitor for metastatic disease (e.g., abiraterone, enzalutamide, apalutamide, darolutamide) b. Subjects with known BRCA mutation positive status should have recevied PARP inhibitor therapy before trial entry (unless contraindicated or unavailable)
排除标准
- •1.History of malignancies other than adequately treated non-melanoma skin cancer or other solid tumors curatively treated with no evidence of disease for =3 years, 2.Adenocarcinoma of the prostate with a small cell component, and with =10% neuroendocrine type cells, 3.Prior treatment with a phosphoinositide 3 kinase (PI3K) inhibitor, a protein kinase B (AKT) inhibitor, or a mechanistic target of rapamycin (mTOR) inhibitor, 4.Prior treatment with chemotherapy or radiopharmaceutical therapy for mCRPC a. Prior docetaxel in combination with ADT and ARi (darolutamide or abiraterone) for castration sensitive prostate cancer (CSPC) is allowed., 5.Subjects with uncontrolled type 1 or type 2 diabetes, 6.Known active human immunodeficiency virus (HIV) infection a.Subjects with well-controlled HIV infection may be allowed if CD4+ T-cell (CD4+) counts >350 cells/µL b.Subjects without a history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections may be eligible for enrollment, 7.Known history/positive serology for acute or chronic hepatitis B virus (HBV) infection (unless immune due to vaccination or resolved natural infection): a.Positive test for antibodies to hepatitis B core antigens (anti-HBc), and negative test for antibodies to hepatitis B surface antigens (anti-HBs) b.Positive for HBsAg, 8.Known seropositive for, or active infection with, hepatitis C virus (HCV) a.Subjects with positive hepatitis C virus antibodies are eligible with negative PCR test for HCV, 9.Known and untreated, or active, brain or leptomeningeal metastases a.Subjects with previously treated central nervous system (CNS) metastases may be enrolled in the study if they meet the following criteria: do not require supportive therapy with steroids; do not have seizures and do not exhibit uncontrolled neurological symptoms; stable disease confirmed by radiographic assessment within at least 4 weeks prior to randomization., Subjects with rapidly progressive disease who are eligible for standard chemotherapy are excluded from enrollment., 10.History of clinically significant cardiovascular abnormalities, 11.Gastrointestinal tract disease resulting in an inability to absorb oral medication as well as history of inflammatory bowel disease, 12.Unable to swallow oral medication tablets/capsules, 13.On more than 10 mg of prednisolone/prednisone (or equivalent) per day, 14.Known hypersensitivity to the study drugs or their components, 15.History of drug-induced pneumonitis or interstitial lung disease, 16.Current uncontrolled medical conditions that, in the opinion of the Investigator, could limit a subject’s ability to undertake study therapy or comply with study requirements, 17.Current participation in another interventional clinical trial: a. Subjects must agree not to participate in another clinical trial (other than observational trials) at any time during participation in CELC-G-201.
研究者
相似试验
已完成
2 期
A Randomized, Open-Label, Dose Finding, Phase 2 Study to Assess the Pharmacodynamics and Safety of the anti-FGF23 antibody, KRN23, in Pediatric Patients with X-linked Hypophosphatemia (XLH)Inheritable from or rickets10027424NL-OMON45206ltragenyx Pharmaceuticals Inc.8
进行中（未招募）
1 期
A Phase 2 Dose-Finding Study of Pacritinib in Myelofibrosis PatientsEUCTR2017-001772-28-SECTI BioPharma Corp.150
进行中（未招募）
1 期
A Phase 2 Dose-Finding Study of Pacritinib in Myelofibrosis PatientsPrimary Myelofibrosis, Post-essential thrombocythemia myelofibrosis,Post polycythaemia vera myelofibrosisMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074692Term: Post essential thrombocythaemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001772-28-ITCTI BIOPHARMA CORP.165
进行中（未招募）
1 期
A Phase 2 Dose-Finding Study of Pacritinib in Myelofibrosis PatientsPrimary Myelofibrosis, Post-essential thrombocythemia myelofibrosis, Post polycythaemia vera myelofibrosisMedDRA version: 20.0Level: PTClassification code 10077161Term: Primary myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10074692Term: Post essential thrombocythaemia myelofibrosisSystem Organ Class: 100000012930MedDRA version: 20.0Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 100000012930MedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001772-28-FRCTI BioPharma Corp.105
进行中（未招募）
1 期
A Phase 2 Dose-Finding Study of Pacritinib in Myelofibrosis PatientsPrimary Myelofibrosis, Post-essential thrombocythemia myelofibrosis, Post polycythaemia vera myelofibrosisMedDRA version: 20.0Level: PTClassification code 10077161Term: Primary myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10074692Term: Post essential thrombocythaemia myelofibrosisSystem Organ Class: 100000012930MedDRA version: 20.0Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 100000012930MedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001772-28-ESCTI BioPharma Corp.165